Product Name

Ursodiol (Ursodeoxycholic Acid)

CAS Number


LGM Pharma is an API distributor. LGM Pharma supplies APIs as per CGMP with DMF support, subject to availability and manufacturer requirements. LGM Pharma does not sell or supply APIs or finished dosage products to individual patients, doctors, or pharmacies.

Questions? Call our customer API support number 1-(800)-881-8210

Product Name:
Ursodiol (Ursodeoxycholic Acid)
CAS Number:
The drug reduces cholesterol absorption and is used to dissolve (cholesterol) gallstones in patients who want an alternative to surgery.
Mode of Action:

Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells. The main mechanism if anticholelithic. Although the exact process of ursodiol's anticholelithic action is not completely understood, it is thought that the drug is concentrated in bile and decreases biliary cholesterol by suppressing hepatic synthesis and secretion of cholesterol and by inhibiting its intestinal absorption. The reduced cholesterol saturation permits the gradual solubilization of cholesterol from gallstones, resulting in their eventual dissolution.


Ursodiol (also known as ursodeoxycholic acid) is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria. Primary bile acids are produced by the liver and stored in the gall bladder. When secreted into the colon, primary bile acids can be metabolized into secondary bile acids by intestinal bacteria. Primary and secondary bile acids help the body digest fats. Ursodeoxycholic acid helps regulate cholesterol by reducing the rate at which the intestine absorbs cholesterol molecules while breaking up micelles containing cholesterol. Because of this property, ursodeoxycholic acid is used to treat gall stones non-surgically.


Neither accidental nor intentional overdosing with ursodeoxycholic acid has been reported. Doses of ursodeoxycholic acid in the range of 16-20 mg/kg/day have been tolerated for 6-37 months without symptoms by 7 patients. The LD50 for ursodeoxycholic acid in rats is over 5000 mg/kg given over 7-10 days and over 7500 mg/kg for mice. The most likely manifestation of severe overdose with ursodeoxycholic acid would probably be diarrhea, which should be treated symptomatically.

(4R)-4-[(1S, 2S, 5R, 7S, 9S, 10R, 11S, 14R, 15R)-5, 9-dihydroxy-2, 15-dimethyltetracyclo[², ⁷.0¹¹, ¹⁵]heptadecan-14-yl]pentanoic acid
Molecular Mass:
17-beta-(1-Methyl-3-carboxypropyl)etiocholane-3-alpha,7-beta-diol, 3,7-Dihydroxycholan-24-oic acid, 3-alpha,7-beta-Dihydroxy-5-beta-cholanoic acid, 3-alpha,7-beta-Dihydroxycholanic acid, 3-alpha,7-beta-Dioxycholanic acid, 3alpha,7beta-Dihydroxy-5beta-cholan-24-oic acid, 4-10-00-01604 (Beilstein Handbook Reference), 7-beta-Hydroxylithocholic acid, Acide ursodesoxycholique, Acide ursodesoxycholique [INN-French], Acido ursodeossicolico, Acido ursodeossicolico [Italian], Acido ursodeoxicolico, Acido ursodeoxicolico [INN-Spanish], Acidum ursodeoxycholicum, Acidum ursodeoxycholicum [INN-Latin], Actigall, Arsacol, BRN 3219888, CCRIS 5502, Cholit-ursan, Delursan, Destolit, Deursil, EC 204-879-3, EINECS 204-879-3, Litursol, Lyeton, NSC 657950, NSC 683769, Peptarom, Solutrat, UNII-724L30Y2QR, Ursacol, UrSO, Urso 250, Urso DS, Urso Forte, Ursobilin, Ursochol, Ursocholic acid, deoxy-, Ursodamor, Ursodeoxycholate, Ursodeoxycholic acid, Ursodesoxycholic acid, Ursodiol, Ursofalk, Ursolvan
AHFS Code:
General Reference:
General Reference:

  1. Akare S, Jean-Louis S, Chen W, Wood DJ, Powell AA, Martinez JD: Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int J Cancer. 2006 Dec 15;119(12):2958-69. Pubmed
  2. Smith T, Befeler AS: High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Curr Gastroenterol Rep. 2007 Mar;9(1):54-9. Pubmed
  3. Jackson H, Solaymani-Dodaran M, Card TR, Aithal GP, Logan R, West J: Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: A population-based cohort study. Hepatology. 2007 Aug 8;46(4):1131-1137. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

LGM currently offers Monoclonal Antibodies (mAbs) for non-GMP/R&D use. Please inquire about Monoclonal Antibodies produced under GMP conditions.

Questions? Call our customer API support number 1-(800)-881-8210. 

Ask us about this product

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants
  • Technical packages as well as access to filed DMF, ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any submission type based on specific customer requirements

Find an API Product

Generic filters